PI3K mutations or PTEN loss in NSCLC, squamous cell lung carcinoma, breast, prostate, and colorectal cancers results in constitutive AKT/mTOR activation, which consequently augments PD-L1 production. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.